Α5IA
α 5 IA (LS-193,268) is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the GABA A receptor.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
α 5 IA (LS-193,268) is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the GABA A receptor. It binds to α 1 , α 2 , α 3 and α 5 -containing subtypes, with functional selectivity for α 5 -containing subtypes.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1359574986 under CC BY-SA 4.0; modifications have been made.